Evidence map›Paper›PMID 32528280›Full record

ArticleFrontiers in pharmacology2020

Semipermeable Cellulose Beads Allow Selective and Continuous Release of Small Extracellular Vesicles (sEV) From Encapsulated Cells.

Gabriela Zavala, María-Paz Ramos, Aliosha I Figueroa-Valdés, Pablo Cisternas, Ursula Wyneken, Macarena Hernández, Pauline Toa, Brian Salmons, John Dangerfield, Walter H Gunzburg and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Basic Guide for Approaching Drug Delivery with Extracellular Vesicles.International journal of molecular sciences · 2024
    Review
  6. Stem Cell's Secretome Delivery Systems.Advanced pharmaceutical bulletin · 2023
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Gabriela ZavalaConsorcio REGENERO, Chilean Consortium for Regenerative Medicine, Santiago, Chile.
María-Paz RamosConsorcio REGENERO, Chilean Consortium for Regenerative Medicine, Santiago, Chile.
Aliosha I Figueroa-ValdésConsorcio REGENERO, Chilean Consortium for Regenerative Medicine, Santiago, Chile.
Pablo CisternasLaboratory of Neurosciences, Centro de Investigación Biomédica, Universidad de los Andes, Santiago, Chile.
Ursula WynekenLaboratory of Neurosciences, Centro de Investigación Biomédica, Universidad de los Andes, Santiago, Chile.
Macarena HernándezConsorcio REGENERO, Chilean Consortium for Regenerative Medicine, Santiago, Chile.
Pauline ToaAustrianova Singapore Pte Ltd, Singapore, Singapore.
Brian SalmonsAustrianova Singapore Pte Ltd, Singapore, Singapore.
John DangerfieldAustrianova Singapore Pte Ltd, Singapore, Singapore.
Walter H GunzburgDepartment of Pathobiology, Institute of Virology, University of Veterinary Medicine, Vienna, Austria.
Maroun KhouryConsorcio REGENERO, Chilean Consortium for Regenerative Medicine, Santiago, Chile.
Universidad de Los Andes, Chile · CLFraunhofer Chile Research Foundation · CLUniversity of Veterinary Medicine Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical benefit of therapies using Mesenchymal Stem Cells (MSCs) is attributable to their pleiotropic effect over cells and tissues, mainly through their secretome. This paracrine effect is mediated by secreted growth factors and extracellular vesicles (EV) including small EV (sEV). sEV are extra-cellular, membrane encompassed vesicles of 40 to 200 nm diameter that can trigger and signal many cellular responses depending on their cargo protein and nucleic acid repertoire. sEV are purified from cell culture conditioned media using several kits and protocols available that can be tedious and time-consuming, involving sequences of ultracentrifugations and density gradient separations, making their production a major challenge under Good Manufacturing Practices (GMP) conditions. We have developed a method to efficiently enrich cell culture media with high concentrations of sEV by encapsulating cells in semipermeable cellulose beads that allows selectively the release of small particles while offering a 3D culture condition. This method is based on the pore size of the capsules, allowing the release of particles of ≤ 200 nm including sEV. As a proof-of-principle, MSCs were encapsulated and their sEV release rate (sEV-Cap) was monitored throughout the culture and compared to sEV isolated from 2D seeded cells (sEV-2D) by repetitive ultracentrifugation cycles or a commercial kit. The isolated sEV expressed CD63, CD9, and CD81 as confirmed by flow cytometry analysis. Under transmission electron microscopy (TEM), they displayed the similar rounded morphology as sEV-2D. Their corresponding diameter size was validated by nanoparticle tracking analysis (NTA). Interestingly, sEV-Cap retained the expected biological activities of MSCs, including a pro-angiogenic effect over endothelial cells, neuritic outgrowth stimulation in hippocampal neurons and immunosuppression of T cells

Indexed as

Cell-in-a-Box® encapsulationcell therapycellulose sulphate microbeadsdrug delivery systemsecretomesmall extracellular vesiclesstem cells

Identifiers

PMID32528280
PMCPMC7253686
OpenAlexW3026906244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.